Updates from NurExone: Growth Conference Presentation and Website Relaunch
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB:NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at advancing our mission and improving stakeholder engagement.
Related news for (NRXBF)
- NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
- NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
- NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award